Tango Therapeutics, Inc. (TNGX)
- Previous Close
7.11 - Open
7.21 - Bid 7.26 x 100
- Ask 7.31 x 200
- Day's Range
7.15 - 7.62 - 52 Week Range
2.47 - 13.03 - Volume
364,177 - Avg. Volume
601,837 - Market Cap (intraday)
781.044M - Beta (5Y Monthly) 0.84
- PE Ratio (TTM)
-- - EPS (TTM)
-1.11 - Earnings Date Aug 5, 2024 - Aug 9, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
17.57
Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company develops TNG462, an oral small molecule methylthioadenosine-cooperative inhibitor for the treatment for cancers with methylthioadenosine phosphorylase deletions; TNG260, a co-repressor of repressor element-1 silencing transcription -selective inhibitor; TNG348, an ubiquitin-specific protease 1 inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. It has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. Tango Therapeutics, Inc. was founded in 2017 and is headquartered in Boston, Massachusetts.
www.tangotx.comRecent News: TNGX
Performance Overview: TNGX
Trailing total returns as of 5/13/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: TNGX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: TNGX
Valuation Measures
Market Cap
759.14M
Enterprise Value
453.78M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
19.00
Price/Book (mrq)
2.87
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-299.88%
Return on Assets (ttm)
-19.47%
Return on Equity (ttm)
-45.41%
Revenue (ttm)
37.23M
Net Income Avi to Common (ttm)
-111.65M
Diluted EPS (ttm)
-1.11
Balance Sheet and Cash Flow
Total Cash (mrq)
343.6M
Total Debt/Equity (mrq)
14.46%
Levered Free Cash Flow (ttm)
-65.29M
Research Analysis: TNGX
Company Insights: TNGX
TNGX does not have Company Insights